Navigation Links
Manufacturing process developed for HIV microbicide
Date:7/3/2014

Lincoln, Neb., July 3, 2014 Scientists at the University of Nebraska-Lincoln College of Engineering's Biological Process Development Facility have successfully produced a drug compound with potential to block HIV transmission in women.

The compound features the 5P12-Rantes molecule, discovered by scientists at the Mintaka Foundation in Switzerland to block HIV transmission by preventing the virus from attaching to human cells. Mintaka has contracted with the UNL facility to develop the manufacturing method for the compound.

The UNL facility has delivered its first batch of the compound to the non-profit research organization for formulation as a vaginal cream for use in clinical trials in South America. The facility landed the $3.8 million contract in 2010 from Mintaka to develop this biological production process for the microbicide.

The successful production run also confirms that the manufacturing process developed at the BPDF is ready to be transferred to a large-scale manufacturing facility, said Scott Johnson, Good Manufacturing Practices coordinator for the UNL facility.

Robin Offord, Mintaka's executive director, said his organization is "happy with the robust nature of the process developed at BPDF."

"Properly validated GMP production is key to Mintaka's plans to empower women and girls in developing countries with a means of protection from HIV/AIDS," he said. "Already, we have successfully transferred the technology to our collaborating institution in South Africa with excellent pilot scale results."

The BPDF's role in this phase of development illustrates the complexity of bringing drugs to clinical trial, officials said.

Good Manufacturing Practices are the strict guidelines imposed by the Food and Drug Administration for the development and manufacture of all pharmaceuticals, with rigorous procedures to test and validate every aspect of the development and production process.

UNL's BPDF meets those requirements, following strict quality control standards and scrutiny for the pharmaceutical industry, including long-term environmental and water quality testing. Johnson said the facility works closely with its clients to develop processes that will produce material suitable for use in clinical trials.

"A client will present us with a gene product they want expressed," he said. "We develop and optimize that process, then scale it up and move the finalized process to our GMP facility for production."

The successful production of 5P12-Rantes was the first to be completed in the BPDF's recently commissioned GMP plant in Othmer Hall. The GMP plant was the first in the nation to be established on a university campus.


'/>"/>

Contact: Kimberly Tedrow, BPDF media contact
ktedrow2@unl.edu
402-472-1962
University of Nebraska-Lincoln
Source:Eurekalert

Related biology news :

1. Solar panel manufacturing is greener in Europe than China, study says
2. Major breakthrough in stem cell manufacturing technology
3. 3-D Printing and Additive Manufacturing: Preview issue of groundbreaking peer-reviewed journal now available
4. 3D Printing and Additive Manufacturing
5. Manufacturing a new gut to treat GI diseases
6. New technique controls dimensions of gold nanorods while manufacturing on a large scale
7. Training the future biomanufacturing workforce
8. Nanosensors could aid drug manufacturing
9. 3-D Printing and Additive Manufacturing preview issue publishing Fall 2013
10. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
11. Manufacturing crack-resistant lightweight components
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., a ... Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas ... practices and how Proscia improves lab economics and realizes an increase in diagnostic ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
Breaking Biology Technology: